| Recent Announcements |
|
8th Annual Nanotechnology and Sustainability Venture Forum
Ensysce Biosciences to present at 8th Annual Nanotechnology and Sustainability Venture Forum |
|
READ MORE |
|
|
|
"Nanotechnology: The Opportunity for Cancer Treatment"
Bob Gower to give Keynote Speech at Chemical Heritage Society's Joseph Priestly Society Symposium. |
|
| READ MORE |
|
|
|
| Ensysce Biosciences Inc. Appoints Dr. D. Lynn Kirkpatrick as President and CEO. |
|
| READ MORE |
|
|
|
|
|
|
|
 |
|
 |
|
| Ensysce Biosciences, Inc. is focused on the use of fullerene carbon nanotubes as delivery agents for cancer therapeutics. |
|
| Carbon nanotubes' unique chemical structure allows them to form stable complexes with cancer-cell targeted agents ranging from small interfering RNA (siRNA) to currently existing cancer drugs such as taxol and doxorubicin. Carbon nanotube complexes can carry these active agents into cancer cells as payloads, protecting them during transport, and, importantly, releasing the payload once inside the cancer cells. All of these features make carbon nanotubes ideal for use with many active macromolecules. |
|
|
 |
|
 |
|
|
 |
|
| Ensysce Biosciences, Inc. is focused on the use of fullerene carbon nanotubes for novel therapeutic applications specifically in the area of cancer treatment. The use of fullerene carbon nanotubes has the goal of solving ... |
|
READ MORE |
|
 |
 |
|
| Ensysce Biosciences is accelerating the use of fullerene carbon nanotubes in therapeutics by funding fundamental discovery research programs at medical centers and universities. Scientists with extensive experience in cancer therapeutics and ... |
|
| READ MORE |
|
|
|
|
|
